Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.

① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?

cls.cnMay 9 18:07

Market Overview | All three major indices fell, with the Tech Index down nearly 1.5%; most Network Technology stocks retraced, with Meituan falling over 5%; Biomedical stocks performed remarkably, with Asymchem Laboratories rising over 11%.

Network Technology stocks fell across the board, with JD-SW down 6.19% and MEITUAN-W down 5.15%; Pharmaceutical stocks rallied, with Asymchem Laboratories up 11.50% and INNOVENT BIO up 6.80%; Apple Supplier stocks declined overall, with AAC TECH down 2.88% and FIH down 2.74%.

Futu NewsApr 24 16:30

Hong Kong stock movement | CUTIA-B (02487) rose more than 11% at the close, and the company is expected to welcome three major new products in the pipeline by 2025.

CUTIA-B (02487) rose over 11% in late trading, currently up 11.75%, priced at 5.8 Hong Kong dollars, with a transaction amount of 11.5499 million Hong Kong dollars.

Zhitong FinanceApr 24 15:55

CUTIA-B: 2024 Annual Report

HKEXApr 22 20:45 · Announcements

Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%. The impact of China Securities Co.,Ltd.'s tariff policy on the Industry Chain of pharmaceuticals still has uncertainties.

Golden Financial News | Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%, HBM HOLDINGS-B (02142) down 25.43%, CUTIA-B (02487) down 25.13%, YIMING ANGKE-B (01541) down 24.73%, CSTONE PHARMA-B (02616) down 24.68%, LAEKNA-B (02105) down 24.38%, WUXI BIO (02269) down 24.02%, JACOBIO-B (01167) down 23.72%, and WUXI XDC (02268) down 23.45%. According to multiple sources.

Jingwu Financial NewsApr 7 13:23

CUTIA-B (02487.HK): Revenue continues to double & Operation efficiency continues to improve. Focus on new pipeline approval increment opportunities.

The Kedi Group disclosed its 2024 annual report, showing continued high revenue growth doubling, with significant narrowing of losses: for the full year 2024: main revenue was 0.28 billion yuan, +103% year-on-year; net income attributable to shareholders was -0.434 billion, a reduction in losses.

Fangzheng SecuritiesApr 6 19:42